BACKGROUND Our study aimed to verify the prognostic value of circulating tumor cells (CTCs) prior to initial treatment on survival of non-small cell lung cancer (NSCLC) by using meta-analysis and system review of published studies. MATERIALS AND METHODS The PubMed, EMBASE and Cochrane Library were searched, respectively, to identify all studies that addressed the issues of CTCs prior to initial treatment and progression-free survival (PFS) and overall survival (OS). Finally, ten citations were included for analysis and assessment of publication bias by using review manager 5.3 statistical software and STATA 15.0. RESULTS Randomized model analyzing multivariate Cox Proportional Hazards Regression indicated that higher abundance of CTCs significantly predicts poorer prognosis of lung cancer cases basing both on PFS (Z = 2.31, P = 0.02) and OS of advanced cases (Z = 2.44, P = 0.01), and systematic study aslo indicated the similar results. CONCLUSION High CTCs prior to initial treatment can predict shorter PFS and OS in NSCLC, and further studies are warranted in the future.

中文翻译：

---

初始治疗之前循环肿瘤细胞是非小细胞肺癌生存的重要预后因素：一项荟萃分析和系统综述。

背景我们的研究旨在通过荟萃分析和已发表研究的系统综述，来验证初始治疗之前循环肿瘤细胞（CTC）对非小细胞肺癌（NSCLC）生存的预后价值。材料和方法分别检索PubMed，EMBASE和Cochrane库，以鉴定所有解决初始治疗和无进展生存期（PFS）和总体生存期（OS）之前四氯化碳问题的研究。最后，通过使用评论管理器5.3统计软件和STATA 15.0，包括十个引文用于分析和评估出版偏倚。结果随机多因素Cox比例风险回归分析的模型表明，基于PFS的CTC含量较高，预示着肺癌患者的预后较差（Z = 2.31，P = 0。02）和晚期病例的OS（Z = 2.44，P = 0.01），系统性研究也表明了相似的结果。结论初始治疗前高CTC可以预测NSCLC的PFS和OS较短，因此有必要在未来进行进一步的研究。